Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Urology
  4. The Role of Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase-Activating Polypeptide in the Neural Pathways Controlling the Lower Urinary Tract

The Role of Vasoactive Intestinal Polypeptide and Pituitary Adenylate Cyclase-Activating Polypeptide in the Neural Pathways Controlling the Lower Urinary Tract

J Mol Neurosci, 2008 · DOI: 10.1007/s12031-008-9090-6 · Published: November 1, 2008

UrologyPharmacologyNeurology

Simple Explanation

Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are expressed in the neural pathways regulating the lower urinary tract. VIP-immunoreactivity (IR) is present in afferent and autonomic efferent neurons innervating the bladder and urethra, whereas PACAP-IR is present primarily in afferent neurons. These observations raise the possibility that VIP or PACAP have a role in the control of normal or abnormal voiding.

Study Duration
Not specified
Participants
Cats, rats, guinea pigs, hamsters, pigs, dogs, rabbits, mice, and humans
Evidence Level
Not specified

Key Findings

  • 1
    Exogenously applied VIP relaxes bladder and urethral smooth muscle and excites parasympathetic neurons in bladder ganglia.
  • 2
    PACAP relaxes bladder and urethral smooth muscle in some species (pig) but excites the smooth muscle in other species (mouse).
  • 3
    PACAP has presynaptic facilitatory effects and direct excitatory effects on lumbosacral parasympathetic preganglionic neurons.

Research Summary

Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are expressed in the neural pathways regulating the lower urinary tract. VIP-immunoreactivity (IR) is present in afferent and autonomic efferent neurons innervating the bladder and urethra, whereas PACAP-IR is present primarily in afferent neurons. These observations raise the possibility that VIP or PACAP may have a role in the regulation of normal or abnormal voiding.

Practical Implications

Therapeutic Potential

VIP and PACAP pathways could be targeted for treating urinary dysfunctions.

Personalized Medicine

Species-specific responses to VIP and PACAP highlight the need for tailored treatments.

SCI Management

Understanding VIP/PACAP's role post-SCI can improve bladder function recovery strategies.

Study Limitations

  • 1
    Species-specific differences in VIP/PACAP effects.
  • 2
    Incomplete understanding of receptor-specific roles.
  • 3
    Need for more in vivo studies with antagonists/knockouts.

Your Feedback

Was this summary helpful?

Back to Urology